Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy and Surgery for Infantile Fibrosarcoma
NCT00072280Phase 2Terminated
- Sponsor
- Children's Oncology Group
- Start
- Nov 2004
- Primary completion
- Mar 2008
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 4
01
Overview
Phase 2, open-label trial of vincristine sulfate liposome injection, actinomycin D, cyclophosphamide, ifosfamide and etoposide in infantile fibrosarcoma (IFS) (2 arms), sponsored by Children's Oncology Group. Primary endpoints: Event-free Survival at 5 years and Relapse-free Survival at 5 years. Started Nov 2004; status: terminated.
02
Drugs
vincristine sulfate liposome injectionactinomycin Dcyclophosphamideifosfamideetoposide
03
Conditions
infantile fibrosarcoma (IFS)
Beyond the preview
Go deeper on NCT00072280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072280.